Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-TNF + vedolizumab + ustekinumab
- Development stage
- Preclinical
- Lead developer
- Takeda
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
anti-TNF + vedolizumab + ustekinumab is an experimental triple biologic combination therapy investigated for the treatment of refractory inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. This regimen combines an anti-tumor necrosis factor (anti-TNF) agent (such as infliximab, adalimumab, or certolizumab pegol) with vedolizumab (an anti-integrin monoclonal antibody) and ustekinumab (an anti-IL-12/IL-23 monoclonal antibody). By targeting three distinct inflammatory pathways—TNF-alpha, alpha-4-beta-7 integrin, and the p40 subunit of IL-12/IL-23—this triple therapy aims to overcome the therapeutic limitations of monotherapy or dual-targeted therapy in patients with highly refractory disease or overlapping immune-mediated inflammatory conditions.
- Other names
- anti-TNF, vedolizumab, and ustekinumabtriple biologic therapy (anti-TNF + vedolizumab + ustekinumab)
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)IL-12R (Interleukin-12 receptor)IL12B (Interleukin-12/23 p40 subunit)IL23R (Interleukin-23 Receptor)MADCAM1 (Mucosal addressin cell adhesion molecule 1)Neuraminidaseα4β7 (Integrin alpha-4 beta-7 heterodimer)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on anti-TNF + vedolizumab + ustekinumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-TNF + vedolizumab + ustekinumab.